Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 6/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266047 | 0.85 | DPP4 (0.65) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL11539600 | 0.84 | HSD17B10 (0.74) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL2265175 | 0.82 | DPP4 (0.62) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL11750772 | 0.82 | PIM1 (0.75) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL2265218 | 0.81 | MAPT (0.72) | DPP4LMNAHPGDHSD17B10KDM4E | |
| SCHEMBL2268962 | 0.81 | DPP4 (0.64) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL10965004 | 0.80 | PIM1 (0.76) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL2265039 | 0.79 | DPP4 (0.58) | DPP4LMNAKMT2AHPGDHSD17B10 | |
| SCHEMBL2266395 | 0.79 | DPP4 (0.58) | DPP4LMNAHPGDHSD17B10KDM4E | |
| SCHEMBL2268605 | 0.77 | MAPT (0.65) | DPP4LMNAHPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-08-27 | — | — | US | disclosed |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013096820-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | DPP4 4227/4885LMNA 4082/4885KMT2A 2921/4885 |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | DPP4 4227/4885LMNA 4082/4885KMT2A 2921/4885 |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | DPP4 4227/4885LMNA 4082/4885KMT2A 2921/4885 |
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | DPP4 4227/4885LMNA 4082/4885KMT2A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.